One approach is to restore wild-type p53 function in tumor cells through structural reactivation of mutant p53 with small peptides, among which are PRIMA-1 and APR-246 (NCT04419389), as well as strategies targeting the MDM2/MDM4-p53 axis [161,162,163]. This evidence concerns the gene TP53 and neoplasm.